CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11,001 enrolled
Drug / intervention
Linagliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03338803
NCT03338803N/ACompleted

Real World Glycemic Effectiveness of Linagliptin Among Type 2 Diabetes Mellitus Adults by Age and Renal Function

Boehringer Ingelheim·observational·Posted Nov 9, 2017·Updated May 6, 2019

In Brief

An observational study evaluating Linagliptin for Diabetes Mellitus, Type 2. Completed, enrolled 11,001 participants across 1 site.

Detailed Summary

A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 9, 2017
Enrollment StartNov 21, 2017
Primary CompletionFeb 2, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.6 years ago

Interventions

Linagliptindrug

drug